LivaNova logo

LivaNovaNASDAQ: LIVN

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

19 October 2015

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$2.72 B
-44%vs. 3y high
84%vs. sector
119.12
-88%vs. 3y high
92%vs. sector
-44%vs. 3y high
58%vs. sector
-54%vs. 3y high
39%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:23:16 GMT
$50.03-$1.59(-3.08%)

Dividend

No data over the past 3 years
$318.12 M$323.59 M
$318.12 M$32.95 M

Analysts recommendations

Institutional Ownership

LIVN Latest News

LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today.

LivaNova: Economics Should Start Making Sustained Improvements
seekingalpha.com18 October 2024 Sentiment: POSITIVE

LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth.

LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts
benzinga.com04 October 2024 Sentiment: POSITIVE

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks.

LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript
seekingalpha.com31 July 2024 Sentiment: NEUTRAL

LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today.

LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates
zacks.com31 July 2024 Sentiment: POSITIVE

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
globenewswire.com26 July 2024 Sentiment: NEGATIVE

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
accesswire.com23 July 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
globenewswire.com20 July 2024 Sentiment: NEGATIVE

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
prnewswire.com18 July 2024 Sentiment: NEGATIVE

NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
accesswire.com14 July 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ:LIVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

  • 1(current)
  • 2

What type of business is LivaNova?

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

What sector is LivaNova in?

LivaNova is in the Healthcare sector

What industry is LivaNova in?

LivaNova is in the Medical Devices industry

What country is LivaNova from?

LivaNova is headquartered in United Kingdom

When did LivaNova go public?

LivaNova initial public offering (IPO) was on 19 October 2015

What is LivaNova website?

https://www.livanova.com

Is LivaNova in the S&P 500?

No, LivaNova is not included in the S&P 500 index

Is LivaNova in the NASDAQ 100?

No, LivaNova is not included in the NASDAQ 100 index

Is LivaNova in the Dow Jones?

No, LivaNova is not included in the Dow Jones index

When was LivaNova the previous earnings report?

No data

When does LivaNova earnings report?

Next earnings report date is not announced yet